Acute Effect of Folic Acid, Betaine, and Serine Supplements on Flow-Mediated Dilation after Methionine Loading: A Randomized Trial by Olthof, Margreet R et al.
............................................................................................................................................
Acute Effect of Folic Acid, Betaine, and Serine
Supplements on Flow-Mediated Dilation
after Methionine Loading: A Randomized Trial
Margreet R. Olthof
1¤*, Michiel L. Bots
2, Martijn B. Katan
1, Petra Verhoef
1
1 Wageningen Centre for Food Sciences and Wageningen University, Wageningen, Netherlands, 2 Julius Center for Health Sciences and Primary Care,
University Medical Center Utrecht, Utrecht, Netherlands
Trial Registration: clinicaltrials.gov:
NCT00126347
Funding: This study was funded by
the Wageningen Centre for Food
Sciences, which is an alliance of
major Dutch food industries, the
University of Maastricht, TNO Quality
of Life, and the Wageningen
University and Research Centre, with
financial support by the Dutch
government. The funding source
had no involvement in the design of
the study nor influenced the
conduct and the interpretation of
the study results. None of the
authors had a financial or personal
interest or advisory board affiliation
in the organization sponsoring the
research.
Competing Interests: The authors
have declared that no competing
interests exist.
Citation: Olthof MR, Bots ML, Katan
MB, Verhoef P (2006) Acute effect of
folic acid, betaine, and serine
supplements on flow-mediated
dilation after methionine loading: A
randomized trial. PLoS Clin Trials
1(1): e4. DOI: 10.1371/journal.pctr.
0010004
Received: January 26, 2006
Accepted: March 29, 2006
Published: May 19, 2006
DOI: 10.1371/journal.pctr.0010004
Copyright:  2006 Olthof et al. This
is an open-access article distributed
under the terms of the Creative
Commons Attribution License, which
permits unrestricted use,
distribution, and reproduction in any
medium, provided the original
author and source are credited.
Abbreviations: CI, confidence
interval; CV, coefficient of variation;
FMD, flow-mediated dilation; NO,
nitric oxide; NTG, nitroglycerine
* To whom correspondence should
be addressed. E-mail: margreet.
olthof@falw.vu.nl
¤ Current address: Vrije Universiteit
Amsterdam, Faculty of Earth and Life
Sciences, Institute of Health
Sciences, Amsterdam, Netherlands
ABSTRACT
Objectives: We investigated whether reducing post-methionine homocysteine concentra-
tions via various treatments other than folic acid affects vascular function, as measured through
flow-mediated dilation (FMD) of the brachial artery. High fasting and post-methionine
homocysteine concentrations are associated with cardiovascular disease risk, but homocysteine
might be a surrogate marker for low folate status.
Design: This was a randomized, placebo-controlled, double-blind, crossover study.
Setting: The study took place at Wageningen University in Wageningen in the Netherlands.
Participants: Participants were 39 apparently healthy men and women, aged 50–70 y.
Interventions: Participants ingested 10 mg of folic acid, 3 g of betaine, 5 g of serine, and
placebo together with an oral methionine load. Each supplement was tested on two different
days.
Outcome Measures: On each of the eight treatment days, plasma homocysteine
concentrations and FMD were measured before (t ¼ 0 h, fasting) and 6 h (t ¼ 6 h) after
methionine loading.
Results: The mean (6 SD) fasting homocysteine concentrations averaged over the eight test
days were 9.6 6 2.1 lmol/l. Mean fasting FMD was 3.1 6 2.4 FMD%. A methionine load with
placebo increased homocysteine concentrations by 17.2 6 9.3 lmol/l at 6 h after loading,
similar to the increase following methionine loading with folic acid. A methionine load together
with betaine and with serine increased homocysteine by 10.4 6 2.8 lmol/l (p , 0.001 relative
to placebo) and by 12.1 6 8.2 lmol/l (p , 0.001 relative to placebo), respectively. Methionine
loading with placebo did not affect FMD, and neither did methionine loading with folic acid,
betaine, or serine; differences relative to placebo were þ0.7 FMD% (95%CI,  0.6; 1.9), þ0.2
FMD% ( 1.0; 1.3), and þ0.3 FMD% ( 0.8; 1.4), respectively.
Conclusions: Experimentally induced acute changes in homocysteine concentrations did not
affect FMD in healthy volunteers. This implies that potential adverse effects of high
homocysteine concentrations on the cardiovascular system are not mediated through vascular
function. However, homocysteine or folate may affect cardiovascular disease risk through other
mechanisms.
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High plasma total homocysteine concentrations are associ-
ated with higher risk of cardiovascular disease [1,2]. Both
fasting homocysteine and the increase of homocysteine
concentrations after a methionine-loading test predict the
risk of cardiovascular disease [3,4]. However, it remains
uncertain whether a high concentration of homocysteine
itself or whether a low folate status—its main determinant—is
involved in the pathogenesis of cardiovascular disease [5].
Some clinical trials of homocysteine lowering through B-
vitamin treatment support the hypothesis that homocysteine
is a culprit factor in cardiovascular disease [6,7], but others do
not [8–12]. To shed light on this issue, we assessed whether
supplementation with homocysteine-lowering nutrients, e.g.,
folic acid, betaine, and serine, similarly affect the risk of
cardiovascular disease.
Betaine is a methyl donor for remethylation of homocys-
teine into methionine. Serine is the methyl donor for
formation of 5-methyltetrahydrofolate from tetrahydrofo-
late. 5-Methyltetrahydrofolate is subsequently used in reme-
thylation of homocysteine into methionine. Furthermore, in
the ﬁrst step of transsulfuration of homocysteine to cysteine,
serine condenses with homocysteine to form cystathionine
[13]. We previously showed that a single dose of betaine and
of serine together with a methionine load reduces the
increase in plasma homocysteine concentrations following a
methionine load [14–16].
High homocysteine concentrations might increase risk of
cardiovascular disease through impairment of vascular
function, an early marker of the atherosclerotic process.
Vascular function can be assessed noninvasively through
ﬂow-mediated dilation (FMD) of the brachial artery [17,18].
FMD is considered a good alternative for assessing cardio-
vascular disease risk. FMD is associated with endothelial
function in coronary arteries of patients [19,20]. Both
coronary endothelial function [21,22] and FMD [23–28] are
associated with increased mortality and morbidity risk in
patients, as well as in low-risk populations. Patients with
hyperhomocysteinemia have impaired vascular function
relative to healthy controls [29–32]. In addition, methio-
nine-induced hyperhomocysteinemia in healthy participants
also has been shown to lead to impairment in vascular
function [33–43].
One study showed that a high dose of 20 mg of folic acid
prevents the impairment in FMD following methionine
loading, whereas this same dosage did not affect the increase
in plasma homocysteine following methionine loading [33].
On the other hand, another study showed no effect on FMD
of a 5-mg folic acid dose together with methionine loading
[34]. Furthermore, supplementation with folic acid or 5-
methyltetrahydrofolate, the naturally circulating form of
folate, without methionine loading has been shown to acutely
improve vascular function in patients with coronary artery
disease [44,45], in hypercholesterolemic patients [46], and in
patients with diabetes type II [47]. These studies suggest that
folic acid affects FMD through mechanisms largely independ-
ent of homocysteine lowering [45]. There are no data on
effects of betaine and serine supplementation together with
methionine loading on vascular function.
In an attempt to identify whether or not homocysteine
itself is involved in cardiovascular disease etiology, we tested
the effect of the homocysteine-lowering supplements folic
acid, betaine, and serine together with methionine loading on
vascular function, as measured through FMD, in healthy
participants.
METHODS
Participants
Participants were recruited from the pool of volunteers
registered at Wageningen University. Eligible volunteers were
healthy as assessed by routine medical screening and a general
health questionnaire; were between 50 and 70 y old; had a
plasmatotalhomocysteine concentration below26 lmol/l;had
no history of cardiovascular disease; had no hypertension; and
had not used vitamin B supplements more than once a week in
the 3 mo before entering the study. Of those volunteers, 99
participants were assessed for eligibility. Out of 69 eligible
participants,40participants(19males)withthehighestplasma
total homocysteine concentrations were included in this
placebo-controlled, double-blind, crossover study (Table 1).
The study was conducted at the Division of Human Nutrition,
Wageningen University (Wageningen, the Netherlands). The
local medical ethics committee approved the protocol, and all
volunteers gave their written informed consent.
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Editorial Commentary
Background: It is already known from observational studies that people
with high concentrations of homocysteine (an amino acid) in the blood
are at increased risk of disease involving the heart and blood vessels,
known as cardiovascular disease. Some randomized trials have also
shown that lowering homocysteine levels decreases the risk of
cardiovascular disease, but not all trials show this. The mechanisms
linking homocysteine levels and cardiovascular disease are not well
understood. Olthof and colleagues wanted to explore further the
mechanisms linking homocysteine levels and the risk of cardiovascular
disease. The investigators did a trial in healthy volunteers in which
homocysteine concentrations were experimentally raised, then lowered,
over short periods of time. The volunteers took a methionine supple-
ment (an amino acid that is converted to homocysteine in the body) to
raise homocysteine levels and either betaine (a dietary nutrient), serine
(an amino acid), or folic acid (a B vitamin) to lower them. During the trial,
the researchers then looked at how well the volunteers’ arm arteries
functioned, as a surrogate for measuring cardiovascular disease risk.
What this trial shows: The investigators found that functioning of the
volunteers’ arteries, as measured through flow-mediated dilation (FMD),
was not affected by the changes in homocysteine levels that were
brought about in the experiment.
Strengths and limitations: Although the number of participants
analyzed in the trial was small (n¼39), it was large enough to adequately
test the researchers’ hypothesis. The vast majority of participants
received the experimental treatment, with only one participant dropping
out of the study. However, the observations were made over a short
period of time, within 6 h of the experimental treatments being given.
The investigators did not look at clinical outcomes, such as heart disease
or stroke. Therefore, this trial does not provide evidence on whether
altered homocysteine levels cause, or could be manipulated to prevent,
such clinical outcomes.
Contribution to the evidence: This trial adds information on the short-
term effects of changes in homocysteine levels.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.Interventions
We tested four supplements together with a methionine-
loading test (50 mg/kg body weight; all supplements provided
by BUFA B.V. Pharmaceutical Products, Uitgeest, the Nether-
lands). The supplements were (a) 5 g of lactose (placebo); (b)
10 mg of folic acid mixed with 5 g of lactose; (c) 3 g of betaine
mixed with 2 g of lactose; and (d) 5 g of L-serine. For each
participant, we measured the effects of each supplement on
two separate days to get a more precise estimate. Participants
came to the university on 8 d divided over 4 wk (two different
days per week, i.e., Monday and Wednesday or Tuesday and
Thursday). Participants were randomly assigned to a unique
treatment order. They received four supplements together
with a methionine load, each on a different day in random
order spread over the ﬁrst 2 wk. Subsequently, they again
received all four supplements in random order on four
different days spread over the second period of 2 wk. There
was always at least 1 wk in between the repeat treatments with
the same supplements. The study supplements were dissolved
in yoghurt or custard and ingested together with the
methionine. We chose doses of 3 g of betaine and 5 g of
serine because we found in previous studies that these doses
considerably lower plasma homocysteine concentrations
following a methionine load (by 23% and 37%, respectively)
[15,16].
Objectives
We investigated whether reducing post-methionine homo-
cysteine concentrations via folic acid, betaine, and serine
treatment affects vascular function, as measured through
FMD in healthy volunteers.
Outcomes
FMD and plasma homocysteine concentrations were the
primary outcome measures. Serum concentrations of vita-
mins B12 and folate were secondary outcome measures.
FMD. Brachial artery measurements were done in partic-
ipants following an overnight fast on each of the eight
treatment days. On these days, FMD was measured before (t¼
0 h, fasting) and 6 h (t ¼ 6 h) after methionine loading. The
within-participant coefﬁcient of variation (CV ¼f SD/meang
3 100%) for FMD was 57% in our study, and this
corresponded well to previous measurements in our labo-
ratory [48,49].
At the start of each measurement day, participants rested
on a bed for 15 min in a temperature-controlled room (20
oC–25 8C). Subsequently, we measured FMD of the brachial
artery using a 7.5 MHz linear-array transducer of an ATL
Ultramark 9 HDI duplex scanner (Philips Medical Systems,
Bothell, Washington, United States). The measurements were
done at the brachial artery of the right arm, at the site of the
antecubital crease, with an inﬂatable cuff around the
forearm. Arm and ultrasound transducer were held in
position with a specially designed ﬁxture (TAF, developed
by Meijer, Vascular Imaging Center, Julius Center for Health
Sciences and Primary Care, University Medical Centre,
Utrecht, the Netherlands) [49]. We chose a segment of the
artery of at least 10 mm in length with clear lumen and
distinctive vessel walls. All images were 103 zoomed and
electronically focused. We ﬁrst obtained an optimal two-
dimensional B-mode ultrasound image of the brachial artery
at rest and recorded three baseline images to measure
baseline diameter. We then either inﬂated the cuff around
the lower arm to a pressure of 200 mmHg or we inﬂated the
cuff 50 mmHg above systolic blood pressure in cases in which
the systolic blood pressure was .150 mmHg. The pressure
was kept constant for 5 min to induce ischemia in the
forearm and hand, and then the cuff was deﬂated and image
recording was started. In the next 5 min, images of the
brachial artery were frozen every 15 s. All measurements were
done at the end-diastole by the use of the R-wave of the
electrocardiogram. All images were recorded on super-VHS
videotape for ofﬂine analysis.
The ofﬂine reading of ultrasound examinations was done
using Brachial Tools, Version 3.2.6 (Medical Imaging Appli-
cations, Coralville, Iowa, United States) as has been described
in detail elsewhere [49]. One reader, who was unaware of
treatment allocation, read all images at the Vascular Imaging
Centre of the University Medical Center Utrecht. Each scan
was read in duplicate, to limit reading variation. The
coefﬁcient of variation (CV ¼f SD/meang 3 100%) in
calculated FMD% between readings was 27%. The reader
traced the trailing edge of the adventitia–media interface at
the near wall and the leading edge of the media–adventitia
interface at the far wall of the brachial artery over a length of
at least 3 mm. The distance between these interfaces reﬂects
the lumen diameter. FMD was computed as the percent
increase in arterial diameter: FMD% ¼f (maximum minus
baseline)/baselineg 3 100%. For reasons of clarity we use
‘‘FMD%’’ as a unit of FMD measurements.
Blood sampling and laboratory analyses. Venous blood was
taken from the antecubital vein following an overnight fast
and 6 h following methionine loading on each treatment day.
Blood samples for analysis of total homocysteine were
collected in vacutainer tubes containing EDTA. Samples
were mixed and put on ice immediately after collection.
Within 30 min, samples were centrifuged for 20 min at 20003
g at 4 8C. For analyses of vitamins B12 and folate, blood was
collected in vacutainer tubes containing clot activator and a
gel to separate serum and cells. About 30 min after blood was
collected, samples were centrifuged for 15 min at 20003 g at
4 8C. All samples were stored below  70 8C. Samples were
coded to hide the identity and treatment of participants. All
samples obtained from one participant were analyzed in the
same run.
Total homocysteine concentrations (the sum of all oxidized
and reduced forms of homocysteine) were measured by high
performance liquid chromatography with ﬂuorescence de-
.......................................................................................
Table 1. Participant Characteristics at Screening (n ¼ 40)
Characteristic Mean 6 SD
Age (y) 61 6 5
BMI (kg/m
2) 25.1 6 3.4
Blood pressure (mmHg)
Systolic blood pressure 135 6 18
Diastolic blood pressure 76 6 10
Total homocysteine (lmol/l) 11.1 6 2.2
Folate (nmol/l) 18.5 6 5.8
Vitamin B12 (pmol/l) 340 6 108
Vitamin B6 (nmol/l) 70.7 6 23.5
Total cholesterol (mmol/l) 5.7 6 0.8
DOI: 10.1371/journal.pctr.0010004.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Acute Homocysteine Lowering Does Not Affect FMDtection [50]. Serum folate and vitamin B12 were measured
using a commercial chemiluminescent immunoassay system
(IMMULITE 2000, Diagnostic Products Corporation, Los
Angeles, California, United States) [51].
Standardization procedures. During the study, participants
were not allowed to consume supplements containing B
vitamins, antioxidant vitamins (A, beta-carotene, C, and E), or
n-3 fatty acids/ﬁsh oil supplements, and they were instructed
to maintain their physical activity level, dietary habits, and
smoking habits during the study.
Participants ate their self-selected diets, except on the days
prior to every measurement day and during each measure-
ment day when they visited the university. On these days, we
provided the participants with standardized breakfast, lunch,
dinner, and snacks. Participants prepared and ate the foods
at home on the day prior to the measurement day. Coffee and
tea consumption and smoking were not allowed after 6 P.M.,
and dinner had to be consumed before 8 P.M. From 10 P.M.
until after the fasting measurements the next morning (blood
sampling, FMD, and blood pressure), participants were not
allowed to smoke, eat, or drink anything except for water.
The next morning, participants came to the university for
measurements, and they received a standardized breakfast
together with the methionine load and the supplement, and a
lunch and snacks until the measurements were ﬁnished (;6h
after methionine loading). After the measurements, partic-
ipants were free to eat their own foods.
All foods that we provided consisted of normal food
products, but foods rich in protein, folic acid, betaine, or
choline were avoided. Participants were not allowed to
consume any of their own foods during these days, except
for coffee and tea. The ﬁrst time that participants received
the standardized foods, they could choose the amounts they
wanted to eat of the foods we provided and of the coffee and
tea. On all following standardized days, participants received
all foods in amounts similar to what they had consumed the
ﬁrst time, and they were instructed to consume the same
amounts of coffee and tea as they did the ﬁrst time.
Participants were instructed to eat everything that we
provided and not to eat anything else.
Sample Size
We calculated that 30 participants would be required to detect
an absolute difference of 2 FMD% relative to placebo,
assuming the within-person standard deviation of the differ-
ence in FMD is ;3.96 FMD% [48] (power ¼0.8, a ¼ 0.05). We
included 40 participants in our study, anticipating that some
participants might withdraw from the study. The difference of
2 FMD% we chose for the power calculations is also used for
power calculations in other studies [52–54], and in our lab de
Roos et al. [55] showed that replacement of dietary saturated
fatty acids by trans fatty acids impaired FMD by 1.8 FMD%.
Therefore, we assumed that a difference of 2 FMD% in our
studies would be plausible. In addition, a methionine-loading
test increases plasma homocysteine concentrations drastically
and can completely abolish FMD [56]. We assumed that
betaine and serine supplements would largely prevent the
impairment in FMD following methionine loading, because
our previous studies have shown that betaine and serine
supplementation together with methionine loading drastically
reduce post-methionine-loading homocysteine concentra-
tions by 30%–40% [15,16]. Folic acid supplementation can
also prevent the impairment in FMD following methionine
loading, despite the fact that folic acid does not affect post-
methionine-loading homocysteine concentrations [33].
Randomization Procedures
A person not further involved in the study assigned codes to
the study treatments and randomly allocated the selected
participants to a unique treatment order and kept the key in
a sealed envelope. The participants and all others involved in
this study were unaware of treatment allocation. The
principal investigator performed unblinding of the treatment
allocation after the study had ended and laboratory analyses
were complete.
Statistical Analysis
For each FMD measurement, we averaged the duplicate
readings of the ultrasound images. For FMD, plasma homo-
cysteine, serum folate, and vitamin B12 concentrations, we
calculated per participant and per measurement day the
difference between fasting values and values at 6 h after
methionine loading. Subsequently, we calculated the mean of
the duplicate measurements per participant for each treat-
ment. We compared the treatments’ effects on FMD, plasma
homocysteine concentrations, and B-vitamin concentrations
with analysis of variance with repeated measurements
(following the General Linear Models procedure in SPSS,
Version 12.0). If the analysis of variance indicated a statisti-
cally signiﬁcant overall treatment effect, comparisons of
means were performed using the Bonferroni correction, and
95% conﬁdence intervals (CI) corresponding with the differ-
ences in means between the treatments were calculated. The
95%CI for the differences in means between fasting and 6 h
following methionine loading (Table 2) were calculated from
the observed differences assuming a normal distribution. We
did not test for carryover effects since every participant had a
unique treatment order. Moreover, we did not expect carry-
over effects in our study. Previous studies have shown that the
effects on homocysteine concentrations of methionine load-
ing alone [33] or with betaine [14] or with serine [16] all return
to baseline within 24 h. Folic acid does not affect homocys-
teine concentrations following methionine loading, but
effects of folic acid supplementation on FMD also return to
baseline within 24 h[33]. For safety reasons, we always planned
at least 2 d washout in between the measurement days.
All statistical analyses were performed with SPSS, Version
12.0.
Figure 1. Participant Flow and Recruitment Flow Chart
DOI: 10.1371/journal.pctr.0010004.g001
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Participant Flow
Participant ﬂow is show in Figure 1. Volunteers were
recruited from June to September 2002. The intervention
started August 2002 and was completed in July 2003.
Baseline Data
Participant characteristics at screening are shown in Table 1.
Numbers Analyzed
Of those who were enrolled, 39 participants completed the
study. One male participant withdrew due to illness not
related to the study.
Outcomes
Methionine loading with placebo increased mean plasma
homocysteine concentrations from 9.4 lmol/l at baseline to
26.6 lmol/l at 6 h following methionine loading (Table 2).
Betaine reduced this increase in homocysteine concentra-
tions by 40% and serine by 30%, whereas folic acid did not
reduce the increase in plasma homocysteine concentrations
following methionine loading (Table 2).
FMD was not affected by methionine loading with placebo,
nor by combinations of methionine with betaine, with serine,
or with folic acid (Table 2; Figure 2). Differences in FMD
relative to placebo were þ0.2 FMD% ( 1.0; 1.3) following
methionine loading with betaine, þ0.3 FMD% ( 0.8; 1.4)
following methionine loading with serine, and þ0.7 FMD%
(95%CI,  0.6; 1.9) following methionine loading with folic
acid. The mean (6 SD) fasting baseline diameter of the
brachial artery prior to methionine loading together with
placebo, betaine, serine, and folic acid supplementation was
4.23 6 0.75 mm, 4.22 6 0.79 mm, 4.25 6 0.75 mm, and 4.18 6
0.77 mm, respectively. At 6 h following methionine loading
together with placebo, betaine, serine, and folic acid
supplementation, mean baseline diameter was 4.28 6 0.78
mm, 4.27 6 0.85 mm, 4.27 6 0.73 mm, and 4.29 6 0.76 mm,
respectively. Fasting mean baseline diameter of the brachial
artery as well as the difference between fasting and post-
methionine-loading baseline diameters was not signiﬁcantly
different between supplements.
Mean serum folate concentrations decreased from 20.3
nmol/l in the fasting state to 14.0 nmol/l at 6 h after
methionine loading with placebo. As expected, concentra-
tions of serum folate were increased more than 10-fold after
methionine loading together with the folic acid treatment.
Methionine loading together with betaine or serine slightly,
but signiﬁcantly, attenuated the decrease in serum folate
concentrations seen with placebo. The concentration of
vitamin B12 was not affected by the treatments (Table 2).
Adverse Events
No serious adverse events were reported in this study. Non-
serious adverse events occurred 30 times in 15 participants.
The adverse events were diverse and unlikely related to the
treatment. Most commonly occurring events were headache
(six times) and diarrhea (ten times, of which nine times were
reported by one participant).
Discussion
Interpretation
Our study is the ﬁrst we know to investigate the effects of
various homocysteine-lowering supplements on FMD follow-
ing methionine loading. We found that methionine-induced
hyperhomocysteinemia did not impair FMD in healthy
.......................................................................................................................................................................................
Table 2. FMD, Concentrations of Total Plasma Homocysteine, Concentrations of Folate and Vitamin B12 in 39 Participants Who
Ingested Placebo, 3 g of Betaine, 5 g of Serine, and 10 mg of Folic Acid together with a Methionine-Loading Test (50 mg of
Methionine per Kilogram of Body Weight) in Random Order, in Crossover Design
Trial Arm Before Methionine Loading After Methionine Loading Delta
(t ¼ 0 h, fasting) (t ¼ 6 h) (6 h minus 0 h)
Mean 6 SD Mean 6 SD (95% CI)
FMD (FMD%)
Placebo 3.2 6 2.2 3.0 6 1.9  0.2 ( 0.8; 0.5)
Betaine 3.3 6 2.2 3.3 6 2.2  0.0 ( 0.7; 0.6)
Serine 3.1 6 2.3 3.3 6 1.8 0.1 ( 0.6; 0.9)
Folic acid 2.9 6 1.7 3.3 6 2.2 0.5 ( 0.2; 1.1)
Plasma homocysteine (lmol/l)
Placebo 9.4 6 1.9 26.6 6 9.7 17.2 (14.2; 20.2)
a
Betaine 9.5 6 1.9 20.0 6 3.8 10.4 (9.5; 11.4)
b
Serine 9.5 6 2.0 21.6 6 8.5 12.1 (9.4; 14.7)
b
Folic acid 9.9 6 2.1 27.1 6 10.6 17.1 (13.8; 20.5)
a
Serum folate (nmol/l)
Placebo 20.3 6 5.9 14.0 6 3.6  6.4 ( 7.4;  5.3)
a
Betaine 20.2 6 6.1 14.9 6 4.0  5.3 ( 6.2;  4.4)
b
Serine 20.1 6 5.2 14.9 6 3.4  5.2 ( 6.0;  4.4)
b
Folic acid 19.4 6 11.9 232.0 6 103.4 212.6 (177.6; 247.5)
c
Serum vitamin B12 (pmol/l)
Placebo 288 6 93 280 6 89  8(  15; 0)
Betaine 284 6 96 284 6 91 0 ( 7; 7)
Serine 284 6 96 287 6 94 3 ( 4; 9)
Folic acid 290 6 95 284 6 94  6(  13; 1)
Different superscript letters indicate significant differences between supplements (p , 0.05, calculated using the analysis of variance with Bonferroni correction).
DOI: 10.1371/journal.pctr.0010004.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Acute Homocysteine Lowering Does Not Affect FMDelderly volunteers. In addition, we found that the reduction
in the increase in plasma homocysteine concentrations
following methionine loading, by means of several supple-
ments, did not affect FMD. This suggests that homocysteine, if
involved in early pathogenesis of cardiovascular disease, does
not exert its action through a mechanism related to vascular
function in healthy individuals.
We are conﬁdent that we designed and performed our
study well.
First, we selected participants with elevated plasma
homocysteine concentrations, who are expected to have a
greater response to the homocysteine-lowering interventions
than randomly selected individuals.
Second, we standardized the FMD measurement to the
maximum of what is possible in a free-living situation. In
order to reduce the variation in the FMD measurement due
to diet, we provided all foods and standardized coffee and tea
consumption on the days preceding the FMD measurements
and on the mornings of methionine loading until the last
FMD measurement that day. We standardized the timing of
eating and smoking on the evening before measurements and
on the days of the methionine loading. During the entire
study we asked the volunteers to keep physical activity,
smoking, and dietary patterns as usual. The supplements were
ingested under our supervision, and thus noncompliance
could not explain the outcome.
Finally, in order to limit the inﬂuence of variation in FMD
between participants, we chose a crossover design, so that
each participant was his or her own control. Furthermore, in
order to reduce the within-participant variation of the FMD
measurement and the variation in ofﬂine analysis of the
ultrasound images [48], we performed duplicate FMD
measurements in each participant on each treatment and
we did the ofﬂine analysis in duplicate. The FMD measure-
ment itself was performed similar to previous studies done in
our laboratory. In one study FMD was not acutely impaired
after test meals with saturated or trans fatty acids [57].
Overall Evidence and Generalizability
The authors are not aware of published systematic reviews or
meta-analyses on the effect of homocysteine lowering
following a methionine load on FMD. Most previous studies
show that vascular function is impaired after methionine
loading [33–43], although some do not [37,58–60]. An
explanation for the fact that we did not ﬁnd an impairment
in FMD following methionine loading could be that we used a
lower dose of methionine (50 mg of methionine per kilogram
of body weight) than most other studies do (100 mg of
methionine per kilogram of body weight). We chose this
lower dose of methionine because it is more in the
physiological range of dietary methionine intake. Moreover,
other studies have shown that methionine doses in the range
of 10–50 mg/kg effectively increase plasma homocysteine
concentrations and impair FMD [56,61]. In conclusion, it
seems unlikely that the lower dose of methionine explains the
lack of an effect on FMD in our study.
Similar to previous supplementation studies, betaine and
serine supplementation together with methionine loading
effectively reduced the increase in plasma homocysteine
concentrations [14–16]. However, there was no effect on
FMD. We are not aware of other published studies that have
investigated effects of betaine or serine supplementation on
FMD following a methionine load.
Although folic acid has no acute homocysteine-lowering
effect following methionine loading [14], previous studies
have shown that folic acid might acutely affect vascular
function via mechanisms independent from homocysteine
lowering [33,44,45]. Contrary to our expectations, FMD was
not affected by folic acid treatment in our study. This is in
line with one other study in healthy volunteers that ﬁnds no
acute effect on FMD of coadministration of 5 mg of folic acid
together with the methionine load following methionine
loading [34]. However, most studies show that supplementa-
tion with folic acid together with a methionine load [33] or
folic acid [45] or 5-methyltetrahydrofolate [44,46,47] alone
can acutely improve vascular function. We would like to raise
the point that publication bias might have resulted in
underrepresentation of studies that did not ﬁnd impairment
in FMD following a methionine load or of studies that did not
ﬁnd an improvement of FMD following folic acid treatment.
The results of this study are also in line with the ﬁndings of
our study on chronic effects of homocysteine lowering on
FMD after an overnight fast [62].
However, it remains possible that homocysteine affects
vascular function in speciﬁc high-risk populations. For
example, vitamin C improved FMD in homocystinuric
patients, but it did not in control participants [30]. Therefore,
our study leaves open the possibility that homocysteine is
related to vascular function in speciﬁc populations, e.g.,
patients with cardiovascular disease or patients at high risk
for cardiovascular disease.
Study Limitations
We note in passing that fasting homocysteine levels were
lower during the trial than during the screening (on average
9.6 versus 11.1 lmol/l). This could be due to regression to the
mean or other causes. Whatever the cause, it did not affect
our outcomes because it occurred on all treatments. More-
over, we always used the differences between treatments and
placebo as our outcomes. Therefore, we do not expect that
Figure 2. Individual Responses in Plasma Homocysteine Concentrations
Shown are the individual responses in plasma homocysteine concentrations
(in micromoles per liter) from 0 h to 6 h following methionine loading versus
the responses in FMD (FMD%) from 0 h to 6 h following methionine loading
in 39 participants who ingested placebo, 3 g of betaine, 5 g of serine, and 10
mg of folic acid together with a methionine-loading test (50 mg of
methionine per kilogram of body weight) in random order in a crossover
design. Each mark represents the mean of FMD measurements on two
different days in one participant.
DOI: 10.1371/journal.pctr.0010004.g002
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possible regression to the mean affected the interpretation of
our results.
Although we have performed the FMD with utmost care,
there are some methodological issues to discuss. First, we did
not perform a nitric oxide (NO)-independent vasodilation
test, usually done with sublingual nitroglycerine (NTG). The
rationale for such a test is to show whether or not the artery is
capable of responding to NO given directly to participants
(endothelium-independent vasodilation). Since we selected
healthy participants in our study, we assumed that all
participants would have an FMD response and we therefore
did not conﬁrm this with an NTG test. Moreover, treatment
effects on the NTG test were not expected [55,63,64]. As we
have seen an FMD response in all of our participants, we do
not think that the lack of NTG measurements affects the
validity of our ﬁndings.
Second, we did not perform Doppler measurements after
the cuff release. The Doppler measurements reﬂect the
stimulus (i.e., the blood ﬂow) that elicits the FMD response,
and through these measurements one may examine whether
the differences between participants and between visits are
due to differences in exposure to increased blood ﬂow. We
did not perform the Doppler measurements in order to
optimize the measurements of the B-mode imaging. The
time window to switch between B-mode and the Doppler
mode in the ultrasound machine was too short to perform
valid Doppler measurements and at the same time capture
reliable images for lumen diameter measurements within the
ﬁrst period after cuff release, which is the most important
phase in which dilation occurs. However, it is highly unlikely
that the stimulus will differ between visits, as the measure-
ments were done in a standardized manner, by the same
technicians using an identical protocol. Moreover, the FMD
was measured in duplicate on each treatment, which
minimized variations in the FMD responses that were not
due to the treatments. Therefore, the validity of our ﬁndings
is not severely hampered by the lack of the Doppler
measurement.
CONCLUSION
We showed that changes in plasma homocysteine concen-
trations through methionine loading with placebo did not
acutely affect vascular function in healthy elderly volunteers.
Furthermore, methionine loading together with a high dose
of folic acid, betaine, or serine did not affect FMD either.
This may indicate that the potential adverse effects of high
homocysteine on the cardiovascular system are not medi-
ated through changes in vascular function. However,
homocysteine or folate may affect cardiovascular disease
risk through mechanisms other than impaired vascular
function.
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